{"id":7269,"date":"2025-05-21T18:06:27","date_gmt":"2025-05-21T18:06:27","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7269"},"modified":"2025-05-21T18:06:28","modified_gmt":"2025-05-21T18:06:28","slug":"telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","title":{"rendered":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% premium to Telomir\u2019s closing stock price of $2.54 at the time of execution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, the financing includes no warrants, no discounts, and no convertible features, signaling strong insider conviction and a commitment to shareholder-friendly terms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This follows a previous $1 million investment at $7.00 per share in December 2024 from The Starwood Trust, an entity affiliated with the same shareholder group. Telomir also maintains access to a $5 million undrawn, non-dilutive line of credit from the same affiliate, bringing its total insider-backed funding potential to $9 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWe\u2019ve now raised $4 million in equity and secured an additional $5 million in non-dilutive capital\u2014all without toxic structures,\u201d said Erez Aminov, Chairman and CEO of Telomir. \u201cThis capital will directly support the IND submission for Telomir-1 and early clinical work in a rare disease setting.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Telomir-1, the company\u2019s lead candidate, is a first-in-class small molecule designed to reverse cellular aging by targeting five core biological processes, including mitochondrial dysfunction and telomere shortening.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In parallel, the company is developing Telomir-Ag2, a stabilized Silver(II) compound aimed at combating drug-resistant infections.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With a focus on long-term value creation and disciplined capital management, Telomir\u2019s recent raise positions it well to pursue regulatory milestones and clinical progress in the months ahead.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/elon-musk-confirms-tesla-and-xai-to-continue-buying-ai-chips-from-nvidia-and-amd\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Elon Musk Confirms Tesla and xAI to Continue Buying AI Chips from Nvidia and AMD<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[309,359],"tags":[421,416,418,417],"coauthors":[454],"class_list":["post-7269","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","category-small-cap","tag-growth","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T18:06:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T18:06:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program\",\"datePublished\":\"2025-05-21T18:06:27+00:00\",\"dateModified\":\"2025-05-21T18:06:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/\"},\"wordCount\":287,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"keywords\":[\"Growth\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Pharmaceuticals\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/\",\"name\":\"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"datePublished\":\"2025-05-21T18:06:27+00:00\",\"dateModified\":\"2025-05-21T18:06:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/05\\\/21\\\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","og_locale":"en_US","og_type":"article","og_title":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo","og_description":"Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","og_site_name":"Stoxpo","article_published_time":"2025-05-21T18:06:27+00:00","article_modified_time":"2025-05-21T18:06:28+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program","datePublished":"2025-05-21T18:06:27+00:00","dateModified":"2025-05-21T18:06:28+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/"},"wordCount":287,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","keywords":["Growth","Movers","News","Stock Market"],"articleSection":["Pharmaceuticals","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","name":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","datePublished":"2025-05-21T18:06:27+00:00","dateModified":"2025-05-21T18:06:28+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7269"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269\/revisions"}],"predecessor-version":[{"id":7270,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269\/revisions\/7270"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7269"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}